These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38578022)
1. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Cramer P; von Tresckow J; Fink AM; Robrecht S; Giza A; Tausch E; Müller L; Knauf W; Zingerle M; Al-Sawaf O; Langerbeins P; Fischer K; Kreuzer KA; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M Am J Hematol; 2024 Jun; 99(6):1192-1195. PubMed ID: 38578022 [No Abstract] [Full Text] [Related]
2. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596 [TBL] [Abstract][Full Text] [Related]
3. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308 [TBL] [Abstract][Full Text] [Related]
4. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982 [TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. von Tresckow J; Cramer P; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Fürstenau M; Illmer T; Klaproth H; Tausch E; Ritgen M; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst BF; Hallek M Leukemia; 2022 Aug; 36(8):2125-2128. PubMed ID: 35752657 [No Abstract] [Full Text] [Related]
6. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600 [TBL] [Abstract][Full Text] [Related]
7. Current strategies to create tailored and risk-adapted therapies for CLL patients. Cramer P; Eichhorst B; Reinhardt HC; Hallek M Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065 [TBL] [Abstract][Full Text] [Related]
8. COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. Allsup D; Howard D; Emmerson J; Hockaday A; Rawstron A; Oughton JB; Bloor A; Phillips D; Nathwani A; Paneesha S; Turner D; Munir T; Hillmen P Br J Haematol; 2021 Aug; 194(3):646-650. PubMed ID: 34028800 [No Abstract] [Full Text] [Related]
9. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445 [TBL] [Abstract][Full Text] [Related]
11. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743 [TBL] [Abstract][Full Text] [Related]
12. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752 [TBL] [Abstract][Full Text] [Related]